Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MAO-B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MAO-B Catalytic Domain (1-484 aa) & Full-Length Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View MAOB Products |
| Gene Delivery | MAO-B Promise-ORF Lentivirus Mitochondrial-targeted ORF for stable astrocytic/neuronal cell lines. Endotoxin Controlled. |
View MAOB Products |
| Reference Standard | High-Affinity MAO-B Protein Standard For inhibitor binding assays and tracer displacement validation. |
View MAOB Products |
| Benchmark Ab | Anti-MAOB Control Antibody Recombinant positive control for assay validation. |
View MAOB Products |
| Validator | MAO-B siRNA Set (3 unique sequences) For knockdown verification and target specificity confirmation. |
View MAOB Products |
| Selectivity Panel | MAO-A (Paralog) Protein Critical safety counter-screen for selectivity profiling vs. MAO-A. |
View MAOA Products |
| Related Target: COMT | COMT Synergistic target in dopamine metabolism and Parkinson's disease. |
View COMT Products |
| Related Target: SNCA | SNCA Alpha-synuclein pathology pathway partner. |
View SNCA Products |
| Related Target: VMAT2 | SLC18A2 (Vesicular Monoamine Transporter 2) Synergistic pathway in dopamine homeostasis and neuroprotection. |
View SLC18A2 Products |
Critical Assay Challenges & Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (MAOB vs MAOA) | Homolog panel proteins (MAOB and MAOA) strictly verified by mass spec and enzymatic activity assays; >95% purity. |
| Mitochondrial Localization & Conformation | MAO-B Lentivirus for stable cell line construction (HEK293 or SH-SY5Y). Preserves native mitochondrial outer membrane insertion. |
| Irreversible vs Reversible Inhibition Kinetics | High-activity catalytic domain protein (FAD-binding domain intact) for time-dependent inhibition assays. |
| Lack of Controls | Clinical Benchmark positive controls included for reproducible baseline setup. |
| False Positives in Screening | Validated MAO-B siRNA provided for genetic target validation in cellular context. |
Live MAO-B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The MAO-B inhibitor landscape is evolving beyond traditional Parkinson's disease (PD) symptom management toward disease-modifying therapies and oncology applications. While first-generation irreversible inhibitors (Selegiline, Rasagiline) and the newer Safinamide dominate current PD treatment, the next wave targets reversible inhibition with improved selectivity margins to eliminate tyramine-sensitive "cheese effect" risks associated with MAO-A cross-inhibition. Notable R&D directions include multi-target directed ligands (MTDLs) combining MAO-B inhibition with anti-neuroinflammatory, antioxidant, or metal-chelating activities for Alzheimer's disease and neurodegenerative disorders. Emerging research also positions MAO-B as a critical metabolic liability target in glioblastoma and reactive astrocytes, driving demand for cell-permeant inhibitors capable of crossing the blood-brain barrier to disrupt glioma stem cell metabolism. The trend from irreversible to reversible inhibitors and expansion into oncology and neuroprotection represent key shifts in the competitive landscape.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Reversible) | Zambon, Eisai, Novartis, Biogen | Parkinson's Disease, Alzheimer's Disease | Selectivity Assay (Need high-purity MAOB and MAOA proteins); IC50 determination and competitive displacement assays. |
| Small Molecule (Irreversible) | Teva, Lundbeck, Orion | Parkinson's Disease | Covalent binding kinetics, mechanism-based inactivation assays (Need high-activity MAO-B protein). |
| Multi-target Ligand | Various Biotechs | Alzheimer's Disease, Neuroprotection | Enzymatic Profiling (Need highly active recombinant enzymes) for polypharmacology screening. |
| Radioligand / PET Tracer | GE Healthcare, Roche | PD Biomarker (Early diagnosis) | High-affinity MAO-B protein for tracer binding validation and Bmax determination. |
| Combination Therapy / Gene Therapy | AbbVie, Chiesi, Academic | Glioblastoma, Reactive Astrocytes, Neurodegeneration | Cell-based MAO-B overexpression assays (Need Lentivirus stable lines); degradation assays (Need specific antibodies). |
Competitive Modality & Indication Snapshot (Supplement)
This section consolidates additional modalities not fully covered above.
| Modality | Representative Players | Key Indications | Critical Assay Need |
|---|---|---|---|
| PROTAC / Molecular Glue | Emerging Biotechs | Neurodegeneration, Oncology | Degradation assays (Need specific antibodies and cell lines for target engagement). |